{"id":"https://openalex.org/W4206501697","doi":"https://doi.org/10.1007/s11523-021-00865-8","title":"Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System","display_name":"Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System","publication_year":2022,"publication_date":"2022-01-01","ids":{"openalex":"https://openalex.org/W4206501697","doi":"https://doi.org/10.1007/s11523-021-00865-8","pmid":"https://pubmed.ncbi.nlm.nih.gov/35025076","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8783913"},"language":"en","primary_location":{"id":"doi:10.1007/s11523-021-00865-8","doi":"https://doi.org/10.1007/s11523-021-00865-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-021-00865-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00865-8.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00865-8.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031928109","display_name":"Monia Sisi","orcid":"https://orcid.org/0000-0002-0395-6038","observed_orcids":["https://orcid.org/0000-0002-0395-6038"]},"institutions":[{"id":"https://openalex.org/I4210097083","display_name":"IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola","ror":"https://ror.org/00t4vnv68","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210097083"]},{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":true,"raw_author_name":"Monia Sisi","raw_affiliation_strings":["Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy. monia.sisi@studio.unibo.it","Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy"],"raw_orcid":"https://orcid.org/0000-0002-0395-6038","affiliations":[{"raw_affiliation_string":"Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy. monia.sisi@studio.unibo.it","institution_ids":["https://openalex.org/I4210097083","https://openalex.org/I9360294"]},{"raw_affiliation_string":"Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I4210097083","https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060485627","display_name":"Michele Fusaroli","orcid":"https://orcid.org/0000-0002-0254-2212","observed_orcids":["https://orcid.org/0000-0002-0254-2212"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Michele Fusaroli","raw_affiliation_strings":["Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082172565","display_name":"Andrea De Giglio","orcid":"https://orcid.org/0000-0002-0731-5721","observed_orcids":["https://orcid.org/0000-0002-0731-5721"]},"institutions":[{"id":"https://openalex.org/I4210097083","display_name":"IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola","ror":"https://ror.org/00t4vnv68","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210097083"]},{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Andrea De Giglio","raw_affiliation_strings":["Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy","Divisione di Oncologia Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I4210097083","https://openalex.org/I9360294"]},{"raw_affiliation_string":"Divisione di Oncologia Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009379815","display_name":"Francesco Facchinetti","orcid":"https://orcid.org/0000-0001-6313-6341","observed_orcids":["https://orcid.org/0000-0001-6313-6341"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I277688954","display_name":"Universit\u00e9 Paris-Saclay","ror":"https://ror.org/03xjwb503","country_code":"FR","type":"education","lineage":["https://openalex.org/I277688954"]},{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Francesco Facchinetti","raw_affiliation_strings":["Institut Gustave Roussy, Inserm, Biomarqueurs Pr\u00e9dictifs et Nouvelles Strat\u00e9gies Th\u00e9rapeutiques en Oncologie, Universit\u00e9 Paris-Saclay, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave Roussy, Inserm, Biomarqueurs Pr\u00e9dictifs et Nouvelles Strat\u00e9gies Th\u00e9rapeutiques en Oncologie, Universit\u00e9 Paris-Saclay, Villejuif, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I277688954","https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032386417","display_name":"Andrea Ardizzoni","orcid":"https://orcid.org/0000-0003-2678-0714","observed_orcids":["https://orcid.org/0000-0003-2678-0714"]},"institutions":[{"id":"https://openalex.org/I4210097083","display_name":"IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola","ror":"https://ror.org/00t4vnv68","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210097083"]},{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Andrea Ardizzoni","raw_affiliation_strings":["Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy","Divisione di Oncologia Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I4210097083","https://openalex.org/I9360294"]},{"raw_affiliation_string":"Divisione di Oncologia Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069397170","display_name":"Emanuel Raschi","orcid":"https://orcid.org/0000-0003-0487-7996","observed_orcids":["https://orcid.org/0000-0003-0487-7996"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Emanuel Raschi","raw_affiliation_strings":["Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021943811","display_name":"Francesco Gelsomino","orcid":"https://orcid.org/0000-0002-9204-1728","observed_orcids":["https://orcid.org/0000-0002-9204-1728"]},"institutions":[{"id":"https://openalex.org/I4210097083","display_name":"IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola","ror":"https://ror.org/00t4vnv68","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210097083"]},{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Francesco Gelsomino","raw_affiliation_strings":["Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy","Divisione di Oncologia Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental, Diagnostic and Specialty Medicine, Policlinico S. Orsola-Malpighi, Alma Mater Studiorum-University of Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I4210097083","https://openalex.org/I9360294"]},{"raw_affiliation_string":"Divisione di Oncologia Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5031928109"],"corresponding_institution_ids":["https://openalex.org/I4210097083","https://openalex.org/I9360294"],"apc_list":{"value":4190,"currency":"USD","value_usd":4190},"apc_paid":{"value":4190,"currency":"USD","value_usd":4190},"fwci":3.6958,"has_fulltext":true,"cited_by_count":27,"citation_normalized_percentile":{"value":0.94470023,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":98},"biblio":{"volume":"17","issue":"1","first_page":"43","last_page":"51"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.6836000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.6836000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.30079999566078186,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.00559999980032444,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.9589999914169312},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9160000085830688},{"id":"https://openalex.org/keywords/psychiatric-adverse-events","display_name":"psychiatric adverse events","score":0.949999988079071},{"id":"https://openalex.org/keywords/mood-disorders","display_name":"mood disorders","score":0.734000027179718},{"id":"https://openalex.org/keywords/psychosis","display_name":"psychosis","score":0.902999997138977},{"id":"https://openalex.org/keywords/lorlatinib","display_name":"lorlatinib","score":0.9629999995231628},{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":0.9440000057220459},{"id":"https://openalex.org/keywords/ceritinib","display_name":"ceritinib","score":0.8080000281333923},{"id":"https://openalex.org/keywords/alectinib","display_name":"alectinib","score":0.9810000061988831},{"id":"https://openalex.org/keywords/brigatinib","display_name":"brigatinib","score":1.0},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.8870000243186951},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5820000171661377},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.6970000267028809},{"id":"https://openalex.org/keywords/fda-adverse-event-reporting-system","display_name":"FDA Adverse Event Reporting System","score":0.7149999737739563}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8686542510986328},{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.792168140411377},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.7693734169006348},{"id":"https://openalex.org/C2779750558","wikidata":"https://www.wikidata.org/wiki/Q21011233","display_name":"Ceritinib","level":5,"score":0.6638068556785583},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5844858884811401},{"id":"https://openalex.org/C2779220645","wikidata":"https://www.wikidata.org/wiki/Q21099132","display_name":"Alectinib","level":5,"score":0.5665668249130249},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5182404518127441},{"id":"https://openalex.org/C2777105317","wikidata":"https://www.wikidata.org/wiki/Q4686710","display_name":"Adverse Event Reporting System","level":3,"score":0.47141262888908386},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.46159908175468445},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.41124963760375977},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.40877336263656616},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000077547","descriptor_name":"Crizotinib","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077548","descriptor_name":"Anaplastic Lymphoma Kinase","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s11523-021-00865-8","doi":"https://doi.org/10.1007/s11523-021-00865-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-021-00865-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00865-8.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},{"id":"pmid:35025076","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35025076","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8783913","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8783913/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Target Oncol","raw_type":"Text"},{"id":"pmh:oai:cris.unibo.it:11585/857943","doi":null,"is_oa":true,"landing_page_url":"https://link.springer.com/article/10.1007/s11523-021-00865-8","pdf_url":null,"source":{"id":"https://openalex.org/S4306402579","display_name":"Archivio istituzionale della ricerca (Alma Mater Studiorum Universit\u00e0 di Bologna)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210117483","host_organization_name":"Istituto di Ematologia di Bologna","host_organization_lineage":["https://openalex.org/I4210117483"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1007/s11523-021-00865-8","doi":"https://doi.org/10.1007/s11523-021-00865-8","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11523-021-00865-8","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11523-021-00865-8.pdf","source":{"id":"https://openalex.org/S163958984","display_name":"Targeted Oncology","issn_l":"1776-2596","issn":["1776-2596","1776-260X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeted Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4206501697.pdf","grobid_xml":"https://content.openalex.org/works/W4206501697.grobid-xml"},"referenced_works_count":27,"referenced_works":["https://openalex.org/W1575513830","https://openalex.org/W2017757358","https://openalex.org/W2074782882","https://openalex.org/W2099530756","https://openalex.org/W2116720928","https://openalex.org/W2139110945","https://openalex.org/W2147038864","https://openalex.org/W2148613928","https://openalex.org/W2234698903","https://openalex.org/W2581996620","https://openalex.org/W2624310346","https://openalex.org/W2767072667","https://openalex.org/W2784414491","https://openalex.org/W2809202955","https://openalex.org/W2894476389","https://openalex.org/W2902826637","https://openalex.org/W2910845152","https://openalex.org/W2922836343","https://openalex.org/W2989516690","https://openalex.org/W3006257197","https://openalex.org/W3022131485","https://openalex.org/W3046013618","https://openalex.org/W3048441995","https://openalex.org/W3101089668","https://openalex.org/W3141415256","https://openalex.org/W3163989578","https://openalex.org/W3216949974"],"related_works":["https://openalex.org/W7154018713","https://openalex.org/W4224129683","https://openalex.org/W4414208422","https://openalex.org/W4362602223","https://openalex.org/W4377836492","https://openalex.org/W2767655639","https://openalex.org/W7167721998","https://openalex.org/W3216949974","https://openalex.org/W4385633877","https://openalex.org/W4309840698"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,26],"development":[2],"of":[3,17,41,60,102,118,150,162,227,239,242,260,280,290,297],"anaplastic":[4],"lymphoma":[5],"kinase":[6,9],"(ALK)":[7],"tyrosine":[8],"inhibitors":[10,33,87],"(TKIs)":[11],"has":[12],"improved":[13],"the":[14,71,107,163,224,261,265,288],"survival":[15],"outcomes":[16],"patients":[18,42],"with":[19,84,90,184,264,283],"advanced":[20,91],"ALK-rearranged":[21],"non-small-cell":[22],"lung":[23],"cancer":[24],"(NSCLC).":[25],"adverse":[27],"events":[28],"(AEs)":[29],"related":[30],"to":[31,106,124,159],"ALK":[32,65,86,125,298],"are":[34],"fairly":[35],"well":[36],"known;":[37],"notably,":[38],"about":[39,237],"20%":[40],"receiving":[43],"lorlatinib":[44,189,269],"experienced":[45],"cognitive":[46],"effects":[47],"and":[48,109,153,203,217,220,233,250],"behavioral":[49],"alterations":[50],"in":[51,70,88,128,148,236,258],"pivotal":[52],"trials.":[53],"Therefore,":[54],"psychiatric":[55,82,122,174,208,229,281,291],"disorders":[56,212,215],"could":[57],"represent":[58],"AEs":[59,83,123,136,230,282],"special":[61],"interest":[62],"for":[63,155,188,268],"all":[64],"TKIs,":[66],"deserving":[67],"careful":[68],"assessment":[69],"post-marketing":[72],"setting.":[73],"OBJECTIVE:":[74],"We":[75,96],"conducted":[76],"a":[77,166,277,294],"real-world":[78],"pharmacovigilance":[79],"study":[80,275],"on":[81],"marketed":[85],"subjects":[89],"NSCLC.":[92],"PATIENTS":[93],"AND":[94],"METHODS:":[95],"performed":[97],"an":[98,160],"observational,":[99],"retrospective":[100],"analysis":[101],"spontaneous":[103],"reports":[104],"submitted":[105],"Food":[108],"Drug":[110,254],"Administration":[111],"Adverse":[112],"Events":[113],"Reporting":[114],"System":[115],"(FAERS,":[116],"as":[117,180,247,252,293],"December":[119],"2020),":[120],"selecting":[121],"TKIs":[126],"approved":[127],"NSCLC":[129],"(crizotinib,":[130],"ceritinib,":[131],"alectinib,":[132],"brigatinib,":[133],"lorlatinib).":[134],"These":[135],"were":[137,178,210,231,245],"independently":[138],"scrutinized":[139],"by":[140,193],"three":[141],"oncologists":[142],"applying":[143],"predefined":[144],"exclusion":[145],"criteria,":[146],"described":[147],"terms":[149],"clinical/demographic":[151],"features":[152],"assessed":[154],"drug-related":[156],"causality":[157],"according":[158],"adaptation":[161],"WHO-UMC":[164],"system,":[165],"standardized":[167],"probabilistic":[168],"algorithm.":[169],"RESULTS:":[170],"Among":[171],"584":[172],"reported":[173,262],"AEs,":[175],"95":[176],"cases":[177,244],"selected":[179],"potentially":[181],"treatment":[182],"related,":[183],"higher":[185,278],"reporting":[186],"frequency":[187],"(26,":[190],"2.8%),":[191],"followed":[192],"brigatinib":[194],"(10,":[195],"1.2%),":[196],"alectinib":[197],"(18,":[198],"0.7%),":[199],"ceritinib":[200],"(12,":[201],"0.6%),":[202],"crizotinib":[204],"(29,":[205],"0.3%).":[206],"Reported":[207],"symptoms":[209],"mood":[211],"(39),":[213],"psychotic":[214],"(24),":[216],"anxiety,":[218],"agitation,":[219],"irritability":[221],"(25).":[222],"In":[223],"majority":[225],"(74%)":[226],"cases,":[228,263],"serious":[232],"required":[234],"hospitalization":[235],"32%":[238],"patients;":[240],"15.8%":[241],"retained":[243],"considered":[246],"highly":[248],"probable":[249],"69.5%":[251],"probable.":[253],"discontinuation":[255],"was":[256],"recorded":[257],"31.6%":[259],"highest":[266],"proportion":[267,279],"(65.4%).":[270],"CONCLUSION:":[271],"Notwithstanding":[272],"limitations,":[273],"our":[274],"found":[276],"lorlatinib,":[284],"but":[285],"also":[286],"raised":[287],"hypothesis":[289],"reactions":[292],"class":[295],"effect":[296],"TKIs.":[299]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":6}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2022-01-26T00:00:00"}